• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assay – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Is PARP1 a Hero or Villain?

by Bellbrook Labs / Tuesday, 07 March 2023 / Published in Emerging Targets, Innate Immunity
PARP1 as a Hero vs Villain

Not counting histones, PARP1 [Poly(ADP-ribose) Polymerase 1] is the most abundant nuclear protein in mammalian cells. While principally known for its role in various types of DNA repair, recent work expanded it’s repertoire to include genome stability maintenance, chromatin remodeling, DNA methylation/gene expression, cellular differentiation, and cell survival modulation via NAD+/ATP regulation.1 It performs Poly(ADP-ribosyl)ation or PARylation by synthesizing long and branched, negatively charged polymers of ADP-ribose (PAR) onto acceptor proteins in a covalent manner at serine, glutamate, and lysine residues. This post-translational modification alters the function and local environment of acceptor proteins in response to cellular stress signaling. Consuming NAD+ during PARylation, PARP1 produces over 90% of all PAR for addition to acceptor proteins.2

Involvement in DNA Repair Mechanisms

Aside from yeast, PARP1 is evolutionarily conserved in all eukaryotes. Human PARP1 is a 113 kDa, 1014 amino acid protein. It consists of 3 main functional domains: an N-terminal DNA binding domain with 3 zinc finger DNA binding motifs (ZF1, ZF2, and ZF3) and a nuclear localization signal sandwiched between ZF2 and ZF3, an auto-PARylation domain, and a C-terminal catalytic (ADP-ribosyl) transferase domain.

While ZF1 and ZF2 are required to recognize sites of DNA damage, ZF3 couples this recognition with the protein’s catalytic functions. The auto-PARylation domain consists of a BRCA1 motif and a tryptophan-glycine-arginine (WGR) motif that can move along DNA without activating the catalytic domain. The WGR domain acts in concert with ZF1 and ZF3 to bring areas of DNA damage in proximity to the catalytic domain. Within the catalytic domain, the helical motif restrains NAD+ binding until PARP1 binds the DNA damage site. Then, the PARP signature motif presents NAD+ for the creation of PAR and the release of nicotinamide.3

After binding to DNA lesions and recruiting repair mechanisms, PARP1 is usually released via auto-PARylation. Cleaved, truncated, or mutated PARP1 produces free 24 kDa N-terminal DNA binding sequences, and this fragment may remain to inhibit DNA repair, augmenting inflammation and apoptosis. However, even excessive induction of full length, intact PARP1 can lead to cell death via exhaustion of available NAD+ and subsequent ATP supplies. This process is known as parthanatos. The balance between the induction of repair mechanisms and parthanatos is the focus of current research.4

The Two Main Model Systems & Their Opposing Roles

Today, the roles of PARP1 in neurological disease and cancer are still hotly debated. Depending upon the model system employed, it can either be the hero or the villain. Pharmaceutical interventions are known to affect other PARP family members and other proteins that may use NAD+. Animal Knock Out strains present total lack of PARP1 from conception forwards. While these animals are healthy and fertile, they are more susceptible to DNA damage and less susceptible to inflammatory inductions. However, in PARP1 and PARP2 KO models, the animals perish in utero. So, there is some salutary effect of PARP2 for survival. In any event, these two main model systems presently generate conflicting assessments. The weight of the evidence currently suggests that, under mild, short-lived stress, PARP1 is a rescuer. But, when stress is high and prolonged, it acts as a terminator.5

Currently, the construction of “floxed” PARP1 animals offers selective induction of PARP1 functional loss in a chosen time frame, set against the background of differing stress signaling levels. Hopefully, this method can provide more accurate modeling for relevant disease states.

References

1. Wang, Y. et al. (2021) Therapeutic Potentials of Poly (ADP-Ribose) Polymerase 1 (PARP1) Inhibition in Multiple Sclerosis and Animal Models: Concept Revisiting. Advanced Science, 2102853. Review. https://doi.org/10.1002/advs.202102853.

2. Zong, W. et al. (2022) PARP1: Liaison of Chromatin Remodeling and Transcription. Cancers, 14, 4162. Review. https://doi.org/10.3390/cancers14174162.

3. Kamaletdinova, T. et al. (2019) The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers. Cells, 8, 1625. Review. https://doi.org/10.3390/cells8121625.

4. Wanderley, C.W.S. et al. (2022) Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications. Front. Immunol. 13:816642. Review. https://doi.org/10.3389/fimmu.2022.816642.

5. Mao, K and Zhang, G. (2020) The role of PARP1 in neurodegenerative diseases and aging. The FEBS Journal 289. Review. https://doi.org/10.1111/febs.15716.

Tagged under: cancer, DNA repair, Innate Immunity, neurological disease, PARP1

What you can read next

PARG in Human Immunity
Discovering the Emerging Importance of PARG in Immunity
FAK Inhibitors: Thwarting Tumor Growth and Curbing Metastasis
TREX1 Inhibitor Assays
TREX1 Inhibitor Assays May Aid the Discovery Novel HIV Treatments

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Ongoing Puzzle of c-SRC in Cancer Treatment

    Advancements in The Ongoing Puzzle to Understand c-SRC

    Nearly a half-century ago, sequences from the R...
  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...
  • SIRT2 Affects Neurodegenerative Diseases

    SIRT2 Isoforms in Neurodegenerative Diseases & Cancer

    Silent information regulator type 2 (Sirtuin 2 ...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP